The association between methylenetetrahydrofolate reductase C677 &gt; T polymorphisms and risk of pediatric acute lymphoblastic leukemia in Asia

Shi-guang, Lin; Q, Liu; Xiaoming, Zeng

doi:10.4103/0973-1482.145877

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the results indicating a promoting role for the mentioned polymorphisms, some authors have reported a protective role for these polymorphisms against NHL (10,15). Similar to results observed for lymphoma, inconsistent results have also been mentioned regarding the role of A1298C and C677T polymorphisms in leukemia, as some authors have reported a higher risk (23), some a lower risk (24)(25)(26), and some no association (27). Our results are in line with previously reported higher risks for the C677T polymorphism; nevertheless, there are insights that may partly explain inconsistency between these observations.…”

Section: Discussionmentioning

confidence: 97%

C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin lymphoma: southeast Iran

Mashhadi

Miri‐Moghaddam

Arbabi

et al. 2018

Tumori

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin lymphoma: southeast Iran

Mashhadi

Miri‐Moghaddam

Arbabi

et al. 2018

Tumori

View full text Add to dashboard Cite

show abstract

“…The prognosis for children older than 2 years is quite favorable, since a remission of 90% and a cure of 75% can be achieved, and patients with a poor prognosis are younger than this, with translocations of t (4; 11 ) (MLL-AF4), leukocytes greater than 100,000 cells and the presence of the Philadelphia chromosome. 10,11 Lin et al 12 reported the association between methylenetetrahydrofolate reductase (MTHFR) C677>T polymorphisms and risk of pediatric acute lymphoblastic leukemia in Asia. 1803 ALL cases and 4146 controls.…”

Section: Discussionmentioning

confidence: 99%

Acute lymphoblastic leukemia in pediatric epigenetic approach

Yeh¹,

Chable²,

Félix³

et al. 2020

MOJAP

View full text Add to dashboard Cite

Introduction and objectives: Acute lymphoblastic leukemia (ALL) in pediatric patients is an issue that affects the quality of life of the patient and his family, so it is urgent to know the physiology, presentation, and functionality of the cell population that allows determining the more effective treatments. The objective is to review the evidence derived from cohort studies and clinical trials on ALL in pediatric patients. Method: A retrospective study carried out based on the search for cohort studies and clinical trials in the last 10 years in MEDLINE, EMBASE, and Cochrane Controlled Trials Register whose keywords [Acute and Lymphoblastic Leukemia], [epigenetical], [Drug Therapy], [Pediatric]. Results: 87 articles were found based on titles and abstracts, of which 16 focus on the age group and criteria of interest. Of the 10% of the known etiology, genetic alterations are more important. However, there are epigenetic modifications that are important for leukemia to occur, such as DNA methylation, histone modification, and regulation by non-coding RNAs. Discussion/conclusions: Acute lymphoblastic leukemia in a heterogeneous pathology and the study of its molecular biology is very useful to identify therapeutic targets and have greater effectiveness in treatment and increase disease-free survival with a longer-term than the current one. In each proposed treatment scheme, it is sought that there be greater effectiveness and less toxicity as in the AIEOP-BFM ALL or IDA-FLAG schemes.

show abstract

Assessment of the relationship between methylenetetrahydrofolate reductase polymorphism and acute lymphoblastic leukemia: Evidence from an updated meta-analysis

Frikha

2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective The methylenetetrahydrofolate reductase gene C677T polymorphism is closely related to the acute lymphoblastic leukemia. Several case–control studies have investigated this association; however, no conclusions could be drawn. A comprehensive updated meta-analysis is established to explain these contradictions and clarify the overall impact of this variant on the susceptibility to acute lymphoblastic leukemia. Methods Electronic searches were conducted to select published studies prior to June 2018. Pooled odds ratios and stratification analysis were performed under different genetic comparison models, age, and ethnicity. Results Totally, 66 case–control studies including 9619 acute lymphoblastic leukemia cases and 17,396 controls were selected. Our analyses showed that methylenetetrahydrofolate reductase C677T polymorphism was protective mainly in Asian and European countries, under all genetic models and regardless of age, but leukemogenic in mixed population. Conclusion Thus, C677T polymorphism may be a promising acute lymphoblastic leukemia biomarker, but they should be interpreted with caution considering other factors such as folic acid intake, gene–gene and gene–environment interactions.

show abstract

The association between methylenetetrahydrofolate reductase C677 > T polymorphisms and risk of pediatric acute lymphoblastic leukemia in Asia

Abstract: The results indicated that Asian children with TT genotype of MTHFR gene may have less risk of developing ALL.

Cited by 3 publications

References 11 publications

C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin lymphoma: southeast Iran

C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin lymphoma: southeast Iran

Acute lymphoblastic leukemia in pediatric epigenetic approach

Assessment of the relationship between methylenetetrahydrofolate reductase polymorphism and acute lymphoblastic leukemia: Evidence from an updated meta-analysis

Contact Info

Product

Resources

About